WallStreetZenWallStreetZen

NASDAQ: NTRB
Nutriband Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their NTRB stock forecasts and price targets.

Forecast return on equity

Is NTRB forecast to generate an efficient return?

Company
269.16%
Industry
-11.73%
Market
130.33%
NTRB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NTRB forecast to generate an efficient return on assets?

Company
238.19%
Industry
-19.32%
NTRB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NTRB earnings per share forecast

What is NTRB's earnings per share in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
$1.48

NTRB revenue forecast

What is NTRB's revenue in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
$97.3M+4,678.33%
NTRB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NTRB revenue growth forecast

How is NTRB forecast to perform vs Biotechnology companies and vs the US market?

Company
4,678.33%
Industry
19.58%
Market
24.11%
NTRB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NTRB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NTRB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NTRB$3.65N/AN/A
PSTV$6.43$55.00+755.37%Strong Buy
RNXT$0.99$8.25+734.18%Buy
ATOS$5.19$24.50+372.06%Buy
GRML$0.36N/AN/A
View Top Biotech Stocks

Nutriband Stock Forecast FAQ

What is NTRB's earnings growth forecast for 2027-2027?

(NASDAQ: NTRB) Nutriband's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 105.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,288%.

Nutriband's earnings in 2026 is -$30,043,798.

In 2027, NTRB is forecast to generate $17,978,699 in earnings, with the lowest earnings forecast at $17,273,652 and the highest earnings forecast at $18,507,484.

If you're new to stock investing, here's how to buy Nutriband stock.

What is NTRB's revenue growth forecast for 2027-2027?

(NASDAQ: NTRB) Nutriband's forecast annual revenue growth rate of 4,678.33% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 19.58%, and it is also forecast to beat the US market's average forecast revenue growth rate of 24.11%.

Nutriband's revenue in 2026 is $2,036,651.

In 2027, NTRB is forecast to generate $1,182,995,954 in revenue, with the lowest revenue forecast at $1,136,608,722 and the highest revenue forecast at $1,217,786,377.

What is NTRB's forecast return on assets (ROA) for 2027-2027?

(NASDAQ: NTRB) forecast ROA is 238.19%, which is higher than the forecast US Biotechnology industry average of -19.32%.

What is NTRB's Earnings Per Share (EPS) forecast for 2027-2027?

(NASDAQ: NTRB) Nutriband's current Earnings Per Share (EPS) is -$2.58. In 2027, NTRB's EPS is forecast to hit $1.48 (min: $1.42, max: $1.52).

What is NTRB's forecast return on equity (ROE) for 2027-2027?

(NASDAQ: NTRB) forecast ROE is 269.16%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.